BE462012A - - Google Patents
Info
- Publication number
- BE462012A BE462012A BE462012DA BE462012A BE 462012 A BE462012 A BE 462012A BE 462012D A BE462012D A BE 462012DA BE 462012 A BE462012 A BE 462012A
- Authority
- BE
- Belgium
- Prior art keywords
- methyl
- isopropyl
- allyl
- barbituric acid
- acid
- Prior art date
Links
- 239000002253 acid Substances 0.000 claims description 5
- 150000001447 alkali salts Chemical class 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical class CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
<Desc/Clms Page number 1>
:Procédé pour la préparation de solutions aqueuses stables de sels alcalins de l'acide 1-méthyl-5-isopropyl-5-allyl-barbi- turique.
Le sel sodique de l'acide 1-métbyl-5-isopropyl-5-allyl- barbiturique possède, lorsqu'il est injecté, une action immédi- ate, mais de courte durée. Il est par conséquent employé comme narcotique de brève durée en injection intra-veineuse. Les solutions aqueuses des sels alcalins de l'acide 1-méthyl-5- isopropyl-5-allyl-barbiturique ne sont stables que pendant peu
<Desc/Clms Page number 2>
de temps, de telle sorte qu'il faut les préparer immédiatement avant l'emploi.
On a maintenant trouvé qu'on peut obtenir des solutions aqueuses stables pendant un temps prolongé des sels alcalins
EMI2.1
de l'acide 1-méthyl-5-isopropyl-5-allôrl-barbiturique si leur préparation est faite en dissolvant l'acide 1-méthyl-5-iso- propyl-5-allyl-barbiturique dans une lessive alcaline aqueuse en présence de diéthylamide acétique. La dissolution de l'acide 1-méthyl-5-isopropyl-5-allyl-barbiturique en substance dans le stabilisateur avant la neutralisation avec une lessive alcaline peut être facilitée par adjonction de glycérine. On peut sté- riliser ces solutions par chauffage ou par addition d'éther-sel méthylique de l'acide p-oxybenzoïque et d'éther-sel propylique de l'acide p-oxybenzoique.
Les solutions préparées selon ce procédé possèdent le même effet narcotique après une longue conservation et la même toxicité que les solutions fraîchement préparées. Tandis qu'une solution aqueuse à la% du sel sodique de l'acide 1- méthyl-5-isopropyl-5-allyl-barbiturique, chauffée pendant 17 heures à 100 C, se trouble fortement par séparation de produits de décomposition sous forme de gouttes, la solution stabilisée avec la diéthylamide acétique reste limpide et in- colore après le même traitement. L'analyse montre que dans la solution non stabilisée 18,4% du produit de départ sont détruits, tandis que cette décomposition n'est que de 6% dans la solution stabilisée.
Dans une solution stabilisée conser- vée pendant 4 semaines à 23 C, on n'a pas pu constater de pro- duits de décomposition.
Les solutions stabilisées avec la diéthylamide acétique de sels alcalins de l'acide 1-méthyl-5-isopropyl-5-allyl- barbiturique peuvent être utilisées comme médicament.
<Desc/Clms Page number 3>
Exemple.
9,15 parties en poids d'acide 1-méthyl-5-isopropyl-5- allyl-barbiturique sont dissoutes dans un mélange de 18 parties en poids de diéthylamide acétique et 9,5 parties en poids de glycérine à 85% environ, en chauffant légèrement ; solution limpide est refroidie et additionnée de 40 parties en volume de lessive de soude n. La solution est complétée à 100 par- ties en volume avec de l'eau distillée et, après filtration, remplie en ampoules et stérilisée.
Au lieu de la stérilisation par chauffage, on peut aussi obtenir des solutions stériles, si l'on ajoute à celles- ci avant la filtration 0,08 partie en poids d'éther-sel méthylique de l'acide p-oxybenzolque et 0,01 partie en poids d'éther-sel propylique de l'acide p-oxybenzoïque.
<Desc / Clms Page number 1>
: Process for the preparation of stable aqueous solutions of alkali salts of 1-methyl-5-isopropyl-5-allyl-barbituric acid.
The sodium salt of 1-metbyl-5-isopropyl-5-allyl-barbituric acid has, when injected, an immediate action, but of short duration. It is therefore used as a short-acting narcotic by intravenous injection. Aqueous solutions of the alkali salts of 1-methyl-5-isopropyl-5-allyl-barbituric acid are only stable for a short time.
<Desc / Clms Page number 2>
time, so that they must be prepared immediately before use.
It has now been found that aqueous solutions which are stable over a prolonged period of time of the alkali salts can be obtained.
EMI2.1
1-methyl-5-isopropyl-5-allorl-barbituric acid if their preparation is made by dissolving 1-methyl-5-isopropyl-5-allyl-barbituric acid in an aqueous alkaline solution in the presence of acetic diethylamide. Dissolution of 1-methyl-5-isopropyl-5-allyl-barbituric acid in substance in the stabilizer prior to neutralization with alkaline lye can be facilitated by addition of glycerin. These solutions can be sterilized by heating or by adding p-oxybenzoic acid methyl ether salt and p-oxybenzoic acid propyl ether salt.
Solutions prepared by this process have the same narcotic effect after long storage and the same toxicity as freshly prepared solutions. While a 1% aqueous solution of the sodium salt of 1-methyl-5-isopropyl-5-allyl-barbituric acid, heated for 17 hours at 100 ° C., becomes highly cloudy on separation of decomposition products in the form of drops, the solution stabilized with acetic diethylamide remains clear and colorless after the same treatment. Analysis shows that in the unstabilized solution 18.4% of the starting material is destroyed, while this decomposition is only 6% in the stabilized solution.
In a stabilized solution stored for 4 weeks at 23 ° C., no decomposition products could be observed.
Solutions stabilized with acetic diethylamide of alkali salts of 1-methyl-5-isopropyl-5-allyl-barbituric acid can be used as a medicament.
<Desc / Clms Page number 3>
Example.
9.15 parts by weight of 1-methyl-5-isopropyl-5-allyl-barbituric acid are dissolved in a mixture of 18 parts by weight of acetic diethylamide and 9.5 parts by weight of approximately 85% glycerin, in heating slightly; clear solution is cooled and added with 40 parts by volume of sodium hydroxide solution n. The solution is made up to 100 parts by volume with distilled water and, after filtration, filled into ampoules and sterilized.
Instead of sterilization by heating, sterile solutions can also be obtained, if 0.08 part by weight of ether-methyl salt of p-oxybenzole acid and 0, is added to these before filtration. 01 part by weight of ether-propyl salt of p-oxybenzoic acid.
Claims (1)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE462012A true BE462012A (en) |
Family
ID=114531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE462012D BE462012A (en) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE462012A (en) |
-
0
- BE BE462012D patent/BE462012A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0316993B1 (en) | Pharmaceutical compositions containing a derivative of 3-hydroxy-butanoic acid chosen among oligomers of this acid and among esters of this acid or of these oligomers with 1,3-butane-diol | |
| JPS60136512A (en) | Remedy and preventive for hyperlipemia | |
| BE462012A (en) | ||
| EP0601911A1 (en) | Acylamino acids obtained by acylation of protein hydrolipates and antimicrobial, antiparasitic or cosmetic compositions containing them | |
| TR201809354T4 (en) | 5 alpha androstan (alkyl) 3 beta, 5,6 beta triol injection and a method for the preparation thereof. | |
| FI92015C (en) | A method of preparing an injectable antiparasitic composition | |
| RU2372904C2 (en) | Alpha-lipoic (thioctic) acid composition, method for making thereof and therapy | |
| FR2542999A1 (en) | PROCESS FOR THE MANUFACTURE OF LIPOSOME CONTAINING ONE OR MORE STERYLGLUCOSIDES AND STERYLGLUCOSIDES MONOPALMITATES AND NOVEL PRODUCTS THUS OBTAINED | |
| MC1485A1 (en) | PROCESS FOR THE PREPARATION OF AQUEOUS SOLUTIONS OF POTENTIALIZED SULFONAMIDES | |
| FR2516923A1 (en) | NOVEL ORGANIC SALTS OF TETRAMISOLE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
| NO334540B1 (en) | Process for the preparation of a parasiticide for the eradication of parasites in farmed fish | |
| IE47985B1 (en) | Pharmaceutical compositions and their use in the prophylaxis and/or treatment of certain diseases | |
| FR2507891A1 (en) | Herpes, and other viruses having lipidic coatings, control - uses 2,6-di-tert.butyl-para-cresol with synergistic fatty acid deriv. emulsion initiator e.g. glycerol oleate | |
| JPS5953423A (en) | Preparation composition for rectal infusion containing cephalosporin compound | |
| Moore et al. | On the chemistry and bio-chemical and physiological properties of a sapo-glucoside obtained from the seeds of Bassia longifolia (mowrah seeds) | |
| BE494334A (en) | ||
| FR3120523B1 (en) | Process for incorporating salt marsh mother waters into cosmetic compositions, and cosmetic compositions thus prepared | |
| CH167958A (en) | A process for the preparation of a stable and sterilizable oily solution of bismuth mono-a-butylnormal thiolaurate. | |
| CN121489861A (en) | A concentrated solution of etoricoxib for injection and its preparation method | |
| BE333357A (en) | ||
| BE483963A (en) | ||
| BE530472A (en) | ||
| BE541013A (en) | ||
| BE562589A (en) | ||
| CH169591A (en) | A process for the preparation of a stable and sterilizable oily solution of tri-a-butylnormal bismuth thiolaurate. |